



10745 Westside Way, Suite 200

Alpharetta, GA 30009

Tel: +1 (844) 884 5367

Email: [info@vtivision.com](mailto:info@vtivision.com)

[www.vtvision.com](http://www.vtvision.com)

[www.vtvisioninvestors.com](http://www.vtvisioninvestors.com) (for investors)

## ASX Announcement

### Visioneering Technologies, Inc. Appendix 4C and Cash Flow Report

**Atlanta, Georgia, USA 12 April 2018 (13 April 2018 AT):** Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) Contact Lenses has released today its Appendix 4C - Quarterly Cash Flow for the period ended 31 March 2018 (1Q18).

The Company reported unaudited 1Q2018 sales revenue of US\$555,112, a 40% increase over 4Q2017 revenue (US\$395,795), and 392% over the same period last year (1Q2017 revenue US\$112,705), continuing the Company's growth trajectory. Active accounts (eye care professionals that purchased during the quarter) grew to 942, a 29% increase over 4Q2017 (730). Cash receipts from customers for the quarter were US\$632,734 and end of quarter cash on hand was US\$12,193,607.

Net operating cash outflow for the quarter was US\$4,375,373, compared to the previous quarter ended 31 December 2017 net operating cash outflow of US\$3,184,097 as the Company continued to increase the purchase of lenses to satisfy anticipated demand and made investments in sales and marketing activities to support future growth.

Dr. Stephen Snowdy, CEO and Executive Director of Visioneering, said, "VTI is pleased to report another quarter of revenue and active account growth in the first quarter of 2018. We feel 1Q18 revenue was positively impacted by increasing awareness of the clinical benefits of NaturalVue Multifocal in both presbyopic adults and myopic children, by clinical paediatric data that was published in 4Q17 and 1Q18, and by the acceleration in performance of territory managers hired in 2H 2017. In the coming months, we expect the launch of new products, including the NaturalVue Toric and an enhanced NaturalVue Sphere. In addition, with our CE Mark having been granted in January, our Australian Therapeutic Goods Administration approval having been granted in March, and other international filings pending, we are well positioned for international expansion in 2018."

#### Investor Conference Call

Investors are invited to join a conference call on Monday, 16 April at 9.00am AEST (Sunday 15 April 7.00pm US EDT) hosted by Visioneering's CEO, Stephen Snowdy.

To pre-register for the call please use this link:

<https://services.choruscall.com.au/diamondpass/vtvision-262984-invite.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call.

Alternatively you can dial in using the details below at the scheduled call start time.

**Conference ID: 262 984**

**Participant Dial In Numbers**

Australia Toll Free: 1 800 558 698  
Australia Local: 02 9007 3187  
New Zealand Toll Free: 0800 453 055  
Hong Kong: 800 966 806  
Singapore: 800 101 2785  
United Kingdom: 0800 051 8245  
United States: (855) 881 1339  
United Kingdom: 0800 051 8245  
US Local (New York): (914) 202 3258  
US Local (Los Angeles): (909) 235 4020

**For more information, please contact:**

<b>Company</b>	<b>Investor and media relations</b>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: <a href="mailto:ssnowdy@vtivision.com">ssnowdy@vtivision.com</a>	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: <a href="mailto:kwilliamson@buchanwe.com.au">kwilliamson@buchanwe.com.au</a>

**About VTI:**

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue® Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics® technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. VTI also sells and plans additional contact lens products.

**Foreign ownership restrictions:**

VTI's CHESSE Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

#### Name of entity

Visioneering Technologies, Inc.

#### ABN

616 156 248

#### Quarter ended ("current quarter")

March 31, 2018

Consolidated statement of cash flows		Current quarter US\$'000	Year to date (3 months) US\$'000
<b>1.</b>	<b>Cash flows from operating activities</b>		
1.1	Receipts from customers	633	633
1.2	Payments for		
	(a) research and development	(225)	(225)
	(b) product manufacturing and operating costs	(1,141)	(1,141)
	(c) advertising and marketing	(478)	(478)
	(d) leased assets	-	-
	(e) staff costs	(2,351)	(2,351)
	(f) administration and corporate costs	(857)	(857)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	43	43
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
<b>1.9</b>	<b>Net cash from / (used in) operating activities</b>	<b>(4,375)</b>	<b>(4,375)</b>
<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(1)	(1)
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	(14)	(14)
	(e) other non-current assets	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter US\$'000</b>	<b>Year to date (3 months) US\$'000</b>
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(15)</b>	<b>(15)</b>
<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>-</b>	<b>-</b>
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of quarter/year to date	16,584	16,584
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,375)	(4,375)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(15)	(15)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held		
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>12,194</b>	<b>12,194</b>

<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter US\$'000</b>	<b>Previous quarter US\$'000</b>
5.1 Bank balances	250	250
5.2 Call deposits	-	-
5.3 Bank overdrafts	-	-
5.4 Other (#)	11,944	11,944
<b>5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>12,194</b>	<b>12,194</b>

# U.S. Treasury bills, notes, and other high-quality, short term securities that are issued or guaranteed by the U.S. government or by U.S. government agencies.

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter  
US\$'000**

53

-

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

**Current quarter  
US\$'000**

-

-

**8. Financing facilities available**  
*Add notes as necessary for an understanding of the position*

	Total facility amount at quarter end US\$'000	Amount drawn at quarter end US\$'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.


--

9. Estimated cash outflows for next quarter	US\$'000
9.1 Research and development	555
9.2 Product manufacturing and operating costs	1,687
9.3 Advertising and marketing	416
9.4 Leased assets	-
9.5 Staff costs	2,865
9.6 Administration and corporate costs	446
9.7 Other (provide details if material)	-
<b>9.8 Total estimated cash outflows</b>	<b>5,969</b>

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	N/A	N/A
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

**Compliance statement**

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- This statement gives a true and fair view of the matters disclosed.

Sign here:   
 (Director/Company secretary)

Date: 13 April 2018

Print name: Stephen Snowdy

**Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

MKT – PR21 – r4.1